Abstract

A COMPREHENSIVE REVIEW OF NON-SMALL CELL LUNG CANCER MANAGEMENT USING THE REARRANGED DURING TRANSFECTION INHIBITOR PRALSETINIB: THERAPEUTIC AND ANALYTICAL PERSPECTIVES

I Ponnilavarasan*, M Sumithra, N Tamilselvi, V S Thiruvengadarajan

ABSTRACT

NSCLC, which accounts for over 85% of all occurrences of lung cancer, continues to be the leading cause of cancer-related death worldwide. Most patients arrive with advanced disease since their early symptoms were unclear, which leaves them with few alternatives for treatment and a dismal prognosis. One of the molecular causes of NSCLC is rearranged during transfection (RET) gene fusions, which happen in one to two percent of cases. These oncogenic drivers stimulate downstream signaling pathways such PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and JAK/STAT, which in turn increase tumor growth, survival, and metastasis. Targeted inhibition of RET is a promising therapeutic strategy. Pralsetinib, a selective RET tyrosine kinase inhibitor, has demonstrated significant clinical efficacy and long-lasting responses in RET fusion-positive NSCLC, according to findings from the ARROW phase I/II trial. Regulators have approved the drug to treat RET-driven malignancies. It is given orally at a dose of 400 mg once daily. In addition to treatment advancements, reliable analytical methods such as LC-MS/MS and HPLC-MS/MS have been developed to accurately measure pralsetinib in biological matrices, ensuring effective pharmacokinetic and bioanalytical evaluation. These proven techniques help research and clinical applications with their excellent sensitivity, accuracy, and robustness. This study highlights the importance of pralsetinib in precision oncology and individualized treatment plans by thoroughly examining phase I/II trial. Regulators have approved the drug to treat RET-driven malignancies. It is given orally at a dose of 400 mg once daily. In addition to treatment advancements, reliable analytical methods such as LC-MS/MS and HPLC-MS/MS have been developed to accurately measure pralsetinib in biological matrices, ensuring effective pharmacokinetic and bioanalytical evaluation. These proven techniques help research and clinical applications with their excellent sensitivity, accuracy, and robustness. This study highlights the importance of pralsetinib in precision oncology and individualized treatment plans by thoroughly examining 

Keywords: NSCLC, Pralsetinib, RET Inhibitors, RET Gene Fusion, Analytical method.